Xortx Therapeutics (TSE:XRTX) has released an update.
XORTX Therapeutics Inc., a pharmaceutical company specializing in kidney disease treatments, has announced the amendment of the exercise price for over a million outstanding warrants to USD $5.00 per share post-consolidation. The adjustment was approved by the TSX Venture Exchange and applies to warrants from three different private placements, with provisions for forced conversion if the company’s share price exceeds USD $6.50 for ten consecutive days.
For further insights into TSE:XRTX stock, check out TipRanks’ Stock Analysis page.
